Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis

Danish Medical Bulletin

Volumn 58, Issue 4, 2011, Pages

  Nilsson, Anna Christine ^a   Christensen, Anne Friesgaard ^a   Junker, Peter ^a   Lindegaard, Hanne Merete ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; AGE; COMPARATIVE STUDY; DRUG ANTAGONISM; HEALTH SURVEY; MIDDLE AGED; OUTPATIENT; PAIN ASSESSMENT; QUESTIONNAIRE; REGISTER;

AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PAIN MEASUREMENT; PREDNISONE; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955158624     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Huber LC, Distler O, Tarner I et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006;45:669-75.
2. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Hansen A, Hetland ML, Tarp U, Stoltenberg M. DANBIO Annual Report 2009. 2010 https://danbio-online.dk/formidling/dokumentmappe/DANBIO_Aarsrapport%202009.pdf (16 Feb 2011).
4. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
5. Gorter SL, Bijlsma JW, Cutolo M et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-14.
6. Huscher D, Thiele K, Gromnica-Ihle E et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68:1119-24.
7. Caplan L, Wolfe F, Russell AS et al. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007;34:696-705.
8. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 2009;27:807-13.
9. Naumann L, Huscher D, Detert J et al. Anti-tumour necrosis factor α therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment. Ann Rheum Dis 2009;68:1934-6.
10. Thorsen H, Hansen TM, McKenna SP et al. Adaptation into Danish of the Stanford health assessment questionnaire (HAQ) and the rheumatoid arthritis quality of life scale (RAQoL). Scand J Rheumatol 2001;30:103-9.
11. Buttgereit F, da Silva JA, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-22.
12. Pisu M, James N, Sampsel S et al. The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:781-8.